Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.
Type:
Grant
Filed:
December 29, 2011
Date of Patent:
December 2, 2014
Assignee:
RSR Limited
Inventors:
Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
Abstract: Substrates and devices for culturing cells are disclosed, along with methods of using the same. The substrates and devices include top surfaces with one or more divots disposed therein. Each divot is defined by an opening in the top surface, a rounded bottom surface spaced from the opening, and an interior side-wall surface extending between the rounded bottom surface and the opening. The top surface of the substrates and devices are optionally walled to form wells containing one or more divots. The substrates and devices may be used for reaggregating cells, for example, to form small islet cell clusters and for high throughput testing methodologies.
Type:
Grant
Filed:
July 26, 2012
Date of Patent:
November 25, 2014
Assignee:
The University of Kansas
Inventors:
Lisa A. Stehno-Bittel, Karthik Ramachandran
Abstract: Nutritional supplement formulations suitable for specific enhancement of cell and mitochondrial function comprise enriched formulations of phospholipids and chemical precursors containing specifically identified concentrations of phosphatidylglycerol, phosphatidic acid and phosphatidylcholine, and mitochondrial and cell membrane phospholipid molecules as well as other desirable constituents. Methods of enriching extracted sources of cell and mitochondrial membrane molecules and precursors from microbes, plants and other sources are also set forth. The formulae can be combined with nutritional, prebiotic, and probiotic (microbial) factors that increase bioavailability through the digestive tract and increase absorption at the cellular and subcellular levels. These lipid combinations can be used to treat mitochondrial disorders associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in many different forms.
Abstract: Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.
Type:
Grant
Filed:
May 1, 2012
Date of Patent:
October 21, 2014
Assignee:
Kypha, Inc.
Inventors:
Paul Olson, Don W. Moss, Nicholas Staten
Abstract: An instrument system that includes an elongate body, an optical fiber, and a controller is provided. The optical fiber is operatively coupled to the elongate body and has a plurality of strain sensors provided on the optical fiber. Each of the plurality of strain sensors has a reflectivity, wherein one of the plurality of strain sensors has a different reflectivity than another one of the plurality of strain sensors. The controller is operatively coupled to the optical fiber and adapted to: receive one or more signals from the plurality of strain sensors; and determine a position of the elongate body based on the one or more signals.
Type:
Grant
Filed:
September 4, 2012
Date of Patent:
October 21, 2014
Assignee:
Koninklijke Philips Electronics N.V.
Inventors:
Bhaskar S. Ramamurthy, Neal A. Tanner, Robert G. Younge, Randall L. Schlesinger, Eric Udd
Abstract: The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.
Type:
Grant
Filed:
July 9, 2010
Date of Patent:
September 30, 2014
Assignees:
University of Pittsburgh-Of the Commonwealth System of Higher Education, Massachusets Institute of Technology
Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.
Abstract: Disclosed are water-soluble nanoparticles. The water-soluble nanoparticles are each surrounded by a multifunctional group ligand including an adhesive region, a cross linking region, and a reactive region. In the water-soluble nanoparticles, the cross-linking region of the multifunctional group ligand is cross-linked with another cross-linking region of a neighboring multifunctional group ligand.
Type:
Grant
Filed:
July 16, 2012
Date of Patent:
August 12, 2014
Assignee:
Industry-Academic Cooperation Foundation, Yonsei University
Abstract: Methods and materials for delivering biologically active molecules to cells in vitro or in vivo are provided. The methods and materials use carbon nanotubes or other hydrophobic particles, tubes and wires, functionalized with a linking group that is covalently bound to the nanotubes, or, alternatively, to the biologically active molecule, such as a protein. The biologically active molecule is preferably released from the nanotube when the complex has been taken up in an endosome.
Type:
Grant
Filed:
August 3, 2012
Date of Patent:
August 5, 2014
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Hongjie Dai, Nadine Wong Shi Kam, Paul A. Wender, Zhuang Liu
Abstract: Methods for isolating and concentrating bone marrow stromal cells drawn from various surgical sites (for example, the proximal humeral head during rotator cuff repair, or the distal femur during ACL surgery) during arthroscopic or open orthopaedic surgery. The pluripotent cells obtained from the bone marrow aspirate can then be reimplanted during the same surgery to improve healing.
Type:
Grant
Filed:
August 27, 2008
Date of Patent:
July 22, 2014
Assignee:
University of Connecticut
Inventors:
Augustus D. Mazzocca, Mary Beth McCarthy
Abstract: The invention relates to a bone formation agent of porous calcium phosphate having an isotropic sintered structure and, between the particles of the calcium phosphate, statistically distributed pores in a plurality of discrete size ranges. The bone formation agent has at least two, preferably three, discrete pore size distributions. Its porosity has an irregular geometric shape. The sintered particles of the calcium phosphate have a particle size smaller than 63 ?m with a d50 value in the range from 5 to 20 ?m. The interconnecting pore share in the overall porosity is limited to pore sizes less than 10 ?m. The bone formation agent can be used in the form of a granulate or shaped body for bone regeneration. In the case of granulates, the maximum pore diameters are matched to the granulate diameter. The invention relates also to a method of producing the bone formation agent.
Type:
Grant
Filed:
June 25, 2004
Date of Patent:
July 15, 2014
Assignee:
Curasan AG
Inventors:
Fabian Peters, Frank Palm, Joachim Wittner, Ute Reif
Abstract: The present invention provides an artificial nail composition which can easily impart a special appearance to the tip of the finger, and which is an artificial nail material coated on a natural or artificial nail, and is used by coating on the surface of a natural or artificial nail followed by polymerization and, more particularly, an artificial nail composition which is vivid and has a natural color tone having a transparent sensation, that cannot be achieved by a conventionally used artificial nail composition containing an organic and/or inorganic colorant utilizing absorption and/or a scattering phenomenon of light, and imparts special appearance by an interference color.
Abstract: The present invention concerns the reduction of gastro-intestinal methanogenesis in ruminants with the aid of agents that compete for the hydrogen atoms required by methanogens during normal fermentation of ingested feed. The invention in one aspect resides in the findings that both nitrate reductive pathways as well as sulphate reductive pathways outcompete gastro-intestinal methanogenesis in ruminants and, that the methanogenesis reducing effects of nitrate and sulphate are completely additive. At the same time the combined administration of nitrate and sulphate was found to be fully effective to avoid or mitigate the potential problems of nitrite intoxication normally encountered when using nitrate alone, which effect is further enhanced, where necessary, by the addition of a nitrite reducing probiotic micoroorganism.
Type:
Grant
Filed:
July 23, 2010
Date of Patent:
July 8, 2014
Inventors:
Hindrik Bene Perdok, Sander Martijn Van Zijderveld, John Richard Newbold, Rob Bernard Anton Hulshof, David Deswysen, Walter Jan Jozef Gerrits, Jan Dijkstra, Ronald Alfred Leng
Abstract: The present invention relates to DNA loaded gold nanoparticles embedded in sharp carbonaceous carriers useful for higher DNA delivery efficiently into plants. These nanogold embedded carbon matrices are prepared by heat treatment of biogenic intracellular gold nanoparticles. The DNA delivery efficiency is tested on model plants. These materials reveal good dispersion of the transport material, producing a greater number of GUS foci per unit area. The added advantages of the composite carrier are the lower plasmid and gold requirements. Plant cell damage with the prepared carbon supported particles is very minimal and can be gauged from the increased plant regeneration and transformation efficiency compared to that of the commercial micrometer sized gold particles. This can be attributed to the sharp edges that the carbon supports possess, which lead to better piercing capabilities with minimum damage.
Type:
Grant
Filed:
August 3, 2010
Date of Patent:
June 24, 2014
Assignee:
Council of Scientific & Industrial Research
Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.
Type:
Grant
Filed:
December 28, 2011
Date of Patent:
June 17, 2014
Assignee:
RSR Limited
Inventors:
Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
Abstract: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.
Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
Abstract: A scaffold having islet cells or small islet cell clusters attached thereto in a multilayer, and a micro-mold having divots for culturing islets, wherein islet formation is influenced by the shape and dimensions of the divots are disclosed.
Type:
Grant
Filed:
April 6, 2010
Date of Patent:
May 27, 2014
Assignee:
The University of Kansas
Inventors:
Cory Berkland, Lisa A. Stehno-Bittel, Teruna Siahaan, Karthik Ramachandran
Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.